Pharmaceutical Executive January 11, 2022
Ahead of the release of EY’s annual M&A Firepower report this week, sat down with Arda Ural, EY Americas Industry Markets Leader for Health Sciences and Wellness, to review biopharma M&A activity in 2021 and to discuss the likely deal drivers of 2022.
Pharm Exec: How would you sum up 2021 in terms of biopharma deal activity?
Arda Ural: In terms of the deal values and indication, typically you’re looking about $200 billion as a healthy benchmark, over the last ten years or so. This fell below 200 billion in 2021. Through to mid-October, I think we recorded a total value of about $108 billion in biopharma M&A deals. So, clearly the M&A market reflected some of the uncertainty of...